Comunicados à imprensa

Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose

Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026

Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference

Edwards Comments on JenaValve Acquisition

FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy

Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference

Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease

Edwards Lifesciences Announces CFO Transition Plan

Edwards Lifesciences Reports Third Quarter Results

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025

Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025

Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care

Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase

Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025

Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

Edwards Lifesciences Reports First Quarter Results

Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025

Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data

Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on October 24, 2024

Edwards Lifesciences Completes Sale of Critical Care

First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves

Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024

Edwards Lifesciences to Acquire Innovalve

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

Edwards Lifesciences to Sell Critical Care to BD

Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences Reports First Quarter Results

Edwards Lifesciences Reports First Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference

Edwards Lifesciences Reports Fourth Quarter Results

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE

EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023

EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023

DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY

EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA

EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2023

EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023

EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE

EDWARDS ANNOUNCES KEY EVENTS FOR EUROPCR 2022

EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2022

EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022

EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program

TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021

Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On July 29, 2021

Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR

Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff

Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

Edwards Announces Updates From Annual Meeting

Edwards Lifesciences Reports First Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021

Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020

Edwards Lifesciences Reports Second Quarter Results

Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries

Paul LaViolette Appointed To Edwards Lifesciences Board Of Directors

Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott

Edwards Lifesciences To Host Earnings Conference Call On July 23, 2020

Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China

Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair

Edwards Announces Updates From Annual Meeting

Edwards Lifesciences Announces May 2020 Investor Conference Schedule

Edwards Lifesciences Reports First Quarter Results

Edwards Lifesciences To Hold Virtual Annual Meeting Of Stockholders

Edwards Lifesciences To Host Earnings Conference Call On April 23, 2020

Edwards SAPIEN 3 Valve Shows Excellent Results At 2 Years

Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19

Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference

Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On January 30, 2020

Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On October 23, 2019

Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients

Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference

Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On July 23, 2019

Edwards Comments On Updated TAVR National Coverage Determination

Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation

Edwards Announces Milestones For Transcatheter Mitral Program

Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020

Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue

Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

Edwards Lifesciences Reports First Quarter Results

Edwards Lifesciences Completes Acquisition of CASMED

Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019

Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial

Edwards Lifesciences Announces Strategic Investments

Edwards PASCAL Transcatheter System Receives CE Mark

Edwards Lifesciences Enters Into Agreement To Acquire CASMED

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval

Edwards Comments On U.S. Court Decision

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools

Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark

Edwards Comments On German Court Decision

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On October 23, 2018

Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve

Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule

Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference

Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference

Edwards Lifesciences Reports Second Quarter Results

Edwards Comments On CMS Advisory Panel

Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018

Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR

Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference

Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

Edwards Announces Key Events For EuroPCR 2018

Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

Edwards Lifesciences Reports First Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018

Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

Edwards' Acumen Hypotension Prediction Index Launches In The U.S.

Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference

Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018

Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference